Clinical Trial Update: PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of a PD-L1 antibody with a CTLA-4 antibody in patients with advanced intrahepatic cholangiocarcinoma who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• CTLA-4 antibody
• PD-L1 antibody

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Cholangiocarcinoma, Intrahepatic, PD-L1 | Phase 2 | Status: ACTIVE_NOT_RECRUITING